You are here

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Cerritos, California, 90703 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must have a current diagnosis of schizophrenia of paranoid (295.30),
disorganized (295.10), or undifferentiated (295.90) subtype in the residual phase.

- Subjects must be in ongoing maintenance antipsychotic monotherapy with risperidone,
olanzapine, quetiapine, ziprasidone, paliperidone, or aripiprazole. Subjects must be
on a stable medication treatment regimen for at least 2 months.

- Evidence of stable symptomatology at least 3 months.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Female subjects who are pregnant or breastfeeding.

- Subjects with evidence or history of a clinically significant medical condition which
would increase risk or which could interfere with the interpretation of trial results.

- Subjects who have DSM IV defined psychoactive substance dependence (including alcohol
and excluding nicotine and caffeine dependence) within 12 months of screening or
substance abuse within 3 months prior to screening.

NCT00977522
Pfizer
Terminated
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now